Do you check AMH levels to decide on adjuvant chemotherapy in premenopausal patients with node-positive ER+ breast cancer?
Did the ASCO 2024 presentation from RxPONDER change your practice?
Answer from: Medical Oncologist at Community Practice
The short answer is no. The decision to recommend adjuvant chemotherapy for premenopausal, node-positive, ER+ breast cancer is based on the tumor's biology, not the patient's AMH levels. Here are my thoughts:
Role of AMH: AMH levels are not used to decide on chemotherapy. They are used to counsel p...